The Advancing knowledge in ischemic Stroke PatiEnts on oRal Anticoagulants (ASPERA) study aims to investigate characteristics of ischemic stroke cases occurring in patients on oral anticoagulation for atrial fibrillation (AF) or other cardioembolic arrhythmias and to characterize short and long-term outcomes associated with different secondary prevention strategies to prevent stroke recurrences. The ASPERA study is a multicenter, observational, both retrospective and prospective real-world study involving acute ischemic stroke patients occurring on oral anticoagulation. The study will encompass a retrospective (ASPERA-R) and prospective (ASPERA-P) data collection. Patient will be recruited consecutively at different emergency services and stroke units worldwide. University of L'Aquila (UnivAQ) will be in charge of study coordination, data analysis and management. The duration of ASPERA-R will be of 5-year from the study initiation of the study. Participating centers will be given a 6-month timeframe to enter retrospective data, commencing from the date of study approval.
ASPERA-P duration will be of 2 years of enrollment from the study approval and follow-up of 5 years. (study conclusion after 7 years of approval). Inclusion criteria will be: 1.Confirmed diagnosis of ischemic stroke. 2. Availability of at least one neuroimaging exam positive for ischemic lesion(s) consistent with patient symptoms. 3. Ongoing oral anticoagulation at the time of the index ischemic stroke. 4. Prior diagnosis of atrial fibrillation or other cardioembolic arrhythmias. 5. Written informed consent provided by the patient himself or by proxy. Patients with Symptoms not indicative of acute stroke, ongoing intravenous or subcutaneous anticoagulation at the time of stroke will be excluded. ASPERA-R: characterization of demographic, clinical and neuroimaging features of ischemic stroke cases occurring on oral anticoagulants. The primary outcome will be: ASPERA-R : characterization of demographic, clinical and neuroimaging features of ischemic stroke cases occurring on oral anticoagulants. ASPERA-P: risk of ischemic stroke recurrence of ischemic stroke cases occurring on oral anticoagulants across different secondary preventive strategies (i.e., maintaining the same type of oral anticoagulation versus switching to a different secondary prevention strategy) at 90 days, 1 and 5 years after the index stroke. Additionally, the study will aim to investigate the risk of safety events (hemorrhagic transformation, intracranial hemorrhage, other major bleeding events, any bleeding events, death due to any cause), risk of other major ischemic events (transient ischemic attack, myocardial infarction, death due to vascular causes) at each follow-up and to identify demographic, clinical and neuroimaging features of ischemic stroke recurrences.

Start Date12 Feb 2025

Sponsor / Collaborator

University of L'Aquila

NCT06525987

/ Not yet recruitingNot ApplicableIIT

Telecoached Exercise Intervention for Connectivity Enhancement in Small Vessel Disease (TELECONNECT-SVD): a Randomized Clinical Trial

The TELECONNECT-SVD study is a prospective, randomized, multicenter trial aimed at testing the efficacy of a remotely delivered exercise protocol on brain functional connectivity in patients with small vessel disease (SVD)-related ischemic stroke. The study will recruit patients aged ≥60 with a history of lacunar stroke, minimal disability (modified Rankin Scale score 0-1), and low physical activity levels.
The trial will include 60 participants randomized 1:1 to either a 24-week telecoached exercise intervention or usual care. The exercise program consists of multicomponent physical exercises delivered remotely twice a week. Assessments will be conducted at baseline, 12 weeks, 24 weeks, and 48 weeks.
Primary outcomes include changes in brain functional connectivity assessed by high-density EEG and improvements in physical fitness measured by the Senior Fitness Test. Secondary outcomes encompass changes in physical activity levels, anthropometric measurements, and vital signs.
The study employs a "wait list" design, where the control group receives the intervention after the initial 24-week period. This approach allows for assessment of the intervention's immediate effects and the retention of benefits after cessation.
Key features of the protocol include:
* Use of telecoaching to enhance adherence to the exercise program
* Comprehensive assessment of brain connectivity using advanced EEG analysis techniques
* Focus on patients with SVD, who may benefit significantly from exercise interventions
* Evaluation of both neurophysiological and clinical outcomes
The study aims to provide evidence for the potential benefits of exercise in enhancing brain connectivity and physical fitness in SVD patients, potentially informing future treatment guidelines and preventive strategies for this population.

Start Date01 Feb 2025

Sponsor / Collaborator

University of L'Aquila

NCT05816213

/ Not yet recruitingNot ApplicableIIT

Point-of-care Low-field Magnetic Resonance Imaging in Acute Stroke (POCS) Study

Consecutive patients accessing the emergency department with suspected stroke dispatch will be recruited at 3 study units: 1) ASL Abruzzo 1, hospitals of L'Aquila and Avezzano; 2) ASL Abruzzo 2, hospital of Chieti; 3) IRCCS Humanitas Research Hospital of Milan. Anonymized clinical and low-field (LF) MRI data as well as conventional neuroimaging data will be independently assessed by external units (Università Politecnica delle Marche and Policlinico di Messina, respectively). Both units will independently adjudicate the best treatment option, while the latter will also provide historical MRI data of stroke patients to develop artificial intelligence algorithms facilitating LF-MRI images interpretation (Libera Università di Bolzano). Agreement with conventional neuroimaging will be evaluated at different time points (hyperacute, acute -24 h, subacute -72 h, discharge, chronic -4 weeks). Further investigations will include feasibility study to develop an ambulance (mobile stroke unit) equipped with LF-MRI and cost-effectiveness analysis of LF-MRI. This trial will provide necessary data to validate the use of LF-MRI in the acute stroke care.

Start Date01 Feb 2025

Sponsor / Collaborator

University of L'Aquila

100 Clinical Results associated with University of L'Aquila

0 Patents (Medical) associated with University of L'Aquila

23,317

Literatures (Medical) associated with University of L'Aquila

31 Dec 2025·Journal of Dermatological Treatment

Effectiveness, speed of action and safety of brodalumab in elderly psoriasis patients: a multicenter real-world study – IL PSO (Italian Landscape Psoriasis)

Article

Author: Carugno, A. ; Burlando, M. ; Diotallevi, F. ; Pella, P. ; Dal Bello, Giacomo ; Baggini, G. ; Fiorella, C. S. ; Moretta, G. ; Carpentieri, A. ; Galluzzo, M. ; Panasiti, V. ; Fargnoli, M. C. ; Narcisi, A. ; Rizzo, D. ; Sarno, Oriele ; Cozzani, E. ; Campanati, A. ; Zichichi, L. ; Legori, A. ; Calianno, G. ; Esposito, M. ; Graceffa, D. ; De Col, E. ; Cagni, A. E. ; Guarneri, C. ; Brunasso, A. M. G. ; Licciardello, M. ; Vaira, F. ; Cona, F. ; Donnarumma, M. ; Pagnanelli, G. ; Caldarola, Giacomo ; Provenzano, E. ; Musumeci, M. L. ; Rubatto, M. ; Costanzo, A. ; Mola, Federica ; Bianchi, L. ; Dattola, A. ; Travaglini, M. ; Muracchioli, A. ; Di Tano, A. ; Strippoli, D. ; Romita, P. ; Carriero, M. ; Malagoli, P. ; Orsini, D. ; Arancio, L. M. H. ; Musumeci, A. ; Lazzaro Danzuso, Giovanni Carlo ; Campione, E. ; Balestri, R. ; Graziola, F.

31 Dec 2025·HBRC Journal

Comparative analysis of sustainable mobility planning tools: case studies from Italy, Egypt, and Lebanon

Author: Serag, Yehya ; Eugeni, Federico ; Jawad, Dima ; Salem, Talal ; Di Ludovico, Donato

01 Dec 2025·Current Pain and Headache Reports

Epidemiology of Pediatric Chronic Pain: An Overview of Systematic Reviews

Review

Author: Cascino, Miriam ; Varrassi, Giustino ; Latina, Roberto ; Paladini, Antonella ; Viswanath, Omar ; Dabbene, Marcella ; Lo Cascio, Alessio

AbstractPurpose of ReviewChronic non-cancer pain in children and adolescents represents a significant public health issue, affecting physical, psychological, and social well-being. Defined as pain persisting for over three months, this condition is influenced by developmental, socioeconomic, and cultural factors. However, its prevalence remains uncertain and debated. A comprehensive literature search was conducted across electronic databases, including Medline, Embase, CINAHL, PsycINFO, and the Cochrane Library. Eligible systematic reviews were critically appraised using the AMSTAR-2 tool to assess methodological quality. This overview synthesises evidence from existing systematic reviews to provide an updated understanding of the epidemiology and burden of paediatric non-cancer chronic pain.Recent FindingsFindings revealed substantial variability in the reported prevalence of specific pain types: headaches (4–83%), abdominal pain (4–53%), musculoskeletal pain (4–40%), and back/low-back pain (14–24%). Prevalence was generally lower in low- and middle-income countries, likely due to barriers in healthcare access. Methodological heterogeneity was observed across studies, and AMSTAR-2 assessment identified critical limitations in some systematic reviews, impacting the reliability of findings.SummaryThis overview highlights the urgent need for standardised research methodologies to accurately monitor the prevalence of paediatric non-cancer chronic pain. Standardisation is essential for informing policies aimed at mitigating the long-term impact of chronic pain in children and adolescents. Addressing these issues, particularly in resource-limited settings, is crucial for improving health outcomes and reducing societal and economic burdens.

News (Medical) associated with University of L'Aquila

18 Sep 2023

·www.globenewswire.com

Peer-Reviewed Publication of Positive Preclinical Data of SiSaf’s SIS-ADO2 siRNA Program to Treat Rare Genetic Bone Disorder Osteopetrosis

Data published in the Cell Press Journal Molecular Therapy Nucleic AcidsGUILDFORD, United Kingdom, Sept. 18, 2023 (GLOBE NEWSWIRE) -- SiSaf Ltd, an RNA therapeutics company, is pleased to announce the publication in the peer-reviewed journal Molecular Therapy Nucleic Acids(1) of positive in vivo data demonstrating the safety and efficacy of its siRNA therapy for Autosomal Dominant Osteopetrosis 2 (ADO2). The data reported in the paper demonstrate that siRNA complexed with SiSaf’s silicon stabilized hybrid lipid nanoparticles (sshLNP) was able to significantly downregulate expression of an ADO2-specific mutant gene. These results could have significant translational impact on bone disease therapies and open the path to human trials of SiSaf’s potentially curative treatment for Osteopetrosis ADO2. There are currently no approved treatments for this debilitating disease and no other treatments currently in clinical trials. SIS-101-ADO, SiSaf’s lead in house program, is an ADO2-specific siRNA specifically designed against the human CLCN7G215R mRNA formulated with the company’s sshLNP. When tested via single intraperitoneal injection in pre-puberal ADO2 mice, carrying a heterozygous mutation of the Clcn7 gene (Clcn7G213R), SIS-101-ADO significantly downregulated the Clcn7G213R related mRNA levels in femurs at 48 h. Confirmatory results were observed at 2 weeks and 4 weeks after treatments (3 intraperitoneal injections/week), with rescue of the bone phenotype and demonstrating safety. The publication builds on data presented at the American Society of Bone and Mineral Research (ASBMR) 2022 Annual Meeting and is jointly authored by SiSaf and its collaborators from the University of L'Aquila, Italy, led by Professor Anna Maria Teti. Co-author on the paper, Dr. Suzanne Saffie-Siebert, CEO of SiSaf Ltd, said, “Targeting the bone safely and effectively is a challenge for RNA-based therapies. The in vivo data for our ADO2 treatment show that SiSaf’s silicon stabilized LNPs are able to deliver siRNA to the bone without any side effects. This is an important milestone on the path to clinical trials of SiSaf’s treatment for autosomal dominant Osteopetrosis type 2. And it could have wider translational significance for RNA-based treatments of other skeletal disorders.” Professor Anna Maria Teti added, “We can’t wait to see SIS-101-ADO used to treat ADO2 patients and look forward to further collaboration with SiSaf on potential therapies for other skeletal disorders.” SiSaf has had ongoing productive collaboration with Professor Teti’s group for over three years and continues to progress studies in support of its IND data package for SIS-101-ADO. During 2023 it successfully submitted an application to the U.S. FDA for Orphan Drug Designation for SIS-101-ADO which was granted in May. In addition, due to the serious manifestations of this rare skeletal disorder in children, the FDA granted SIS-101-ADO Rare Pediatric Disease Designation for the treatment of Autosomal Dominant Osteopetrosis. 1. Novel hybrid silicon-lipid nanoparticles deliver a siRNA to cure autosomal dominant osteopetrosis in mice. Implications for gene therapy in humans: Molecular Therapy Nucleic Acids: VOLUME 33, P925-937, SEPTEMBER 12, 2023, Antonio Maurizi et. al. https://doi-org.libproxy1.nus.edu.sg/10.1016/j.omtn.2023.08.020 – ABOUT SISAF SiSaf is an RNA therapeutics company with a proprietary delivery platform. Its lead programs are a siRNA treatment for Osteopetrosis ADO2 and a partnered siRNA treatment for Corneal Dystrophy. The company is in the process of expanding its pipeline to other fields, including oncology. SiSaf’s proprietary Bio-Courier™ delivery platform uses silicon stabilized hybrid lipid nanoparticles (sshLNP) to improve the stability, safety, and transfection efficiency of RNA. sshLNP remove the need for an ultra-cold chain and unlike conventional lipid nanoparticles, they can be manufactured empty and the RNA can be introduced in a separate step. Led by founder and leading biomaterials specialist Dr. Suzanne Saffie-Siebert, SiSaf is a venture capital-backed private company. Headquartered in Guildford, UK, it has fully integrated research labs and bio-analytical facilities, a scalable technology to fast-track development, and a growing patent estate with extensive freedom to operate. To learn more, please visit www.sisaf.com Follow us on LinkedIn and Twitter. For further information please contact: MEDIA ENQUIRIES Scius communications Sue Charles – sue@sciuscommunications.com +44 7968726585 Katja Stout – katja@sciuscommunications.com +44 7789435990

Orphan DrugClinical ResultClinical Study

09 Aug 2023

·www.prnewswire.com

NERIVIO® CE MARK INDICATION EXPANDED TO PREVENTIVE AND ACUTE TREATMENT OF MIGRAINE FOR ADOLESCENTS AND ADULTS

The company prepares for bringing the wearable prescribed device to Europe next year NETANYA, Israel, Aug. 9, 2023 /PRNewswire/ -- Theranica, a prescribed digital therapeutics company developing advanced neuromodulation devices for migraine and other pain conditions, today announced it received expanded CE (Conformité Européenne) mark approval under MDR European regulation for Nerivio® as dual-use therapy for both acute and preventive treatment of migraine for adults and adolescents. The CE mark expansion for Nerivio is a critical milestone to accelerate the availability of the novel, drug-free migraine device into the European market. Migraine is a major global neurological disorder that affects over 1 billion people worldwide, with a prevalence higher than one in ten people in Europe. Research shows it's one of the most prevalent disorders, with a high morbidity, especially among young adults and females. Nerivio has been available with prescription in the USA since 2020, initially for acute treatment and since April this year also as a preventive treatment. "Migraine is the leading cause of disability worldwide, including for for adolescents and young adults, and early intervention with preventive treatment is necessary to restrain the disease from escalating", said Dr. Simona Sacco, Professor of Neurology at the University of L'Aquila, Italy, and second vice president of the European Headache Federation. "It is important to expand the treatment options with a non-pharmacological treatment, especially one that can both treat and prevent migraine." "With more than 50,000 prescribed Nerivio patients now in the US, we receive numerous requests, on a weekly basis, to bring the device to Europe," says Alon Ironi, CEO and co-founder of Theranica. "We have been waiting for the prevention indication approval, and with that are now preparing for making Nerivio available for people with Migraine in Europe starting 2024. Our focus is to empower underserved populations, particularly adolescents, to safely and effectively prevent and treat migraines, and be fully present in everyday life." Controlled by a smartphone app and self-administered, Nerivio wraps around the upper arm and uses sub-painful Remote Electrical Neuromodulation (REN) to activate nociceptive nerves fibers in arm to send signals which trigger a descending pain management mechanism in the brain called conditioned pain modulation (CPM), which turns off migraine pain and associated symptoms without medication. In simpler terms, the upper arm is stimulated to unleash a natural process in the brain to abort or relieve migraine headache and other associated symptoms. Each treatment lasts 45 minutes and is applied every other day for prevention or at the start of a migraine attack for acute treatment. About Theranica Theranica is a prescribed digital therapeutics company dedicated to creating effective, safe, affordable, low-side-effect therapies for idiopathic pain conditions. The company's award-winning flagship wearable, Nerivio®, is the first FDA-cleared and CE marked prescription migraine bioband for acute and/or preventive treatment of migraine with or without aura in people 12 years or older. Nerivio already serves more than 50,000 people with migraine in the USA, including adolescents and veterans. Theranica is expanding its proprietary technology to develop solutions for additional idiopathic pain conditions. Learn more by visiting our websites, theranica.com and nerivio.com, and following us on LinkedIn, Twitter, Instagram and Facebook. Theranica Contact Ronen Jashek [email protected] +972-72-390-9750 Media Contact V.A. Lopes Grey Matter Marketing [email protected] SOURCE Theranica

Drug Approval

27 Apr 2023

·www.biospace.com

Dante Genomics receives grant for a whole genome sequencing project to measure utility of pharmacogenomics in a real, clinical setting

– Highly coveted Innovation Grant by the Italian Government will measure impact of whole genome sequencing and pharmacogenomics starting from a specific population of cancer patients -- NEW YORK, April 27, 2023 /PRNewswire/ -- Dante Genomics, a global leader in genomics and precision medicine, today announced it has been awarded a highly coveted Innovation Grant from the Italian Government to measure the impact of whole genome sequencing and pharmacogenomics for patients with High Grade Serous Ovarian Cancer (HSOC). The immediate purpose is to measure the clinical utility of whole genome sequencing for this well-defined population of cancer patients in a clinical setting and the benefits for the entire healthcare system. "Our shared long-term goal is to create a pathway for the use of whole genome sequencing in real, clinical settings in a national healthcare system," said Andrea Riposati, Co-founder and CEO of Dante Genomics. "We are starting in Italy, a European Union founding member and G7 country with a population of 60 million people, and in a healthcare system keen to innovate." The grant will fund a patient pilot study in which Dante will provide sequencing, interpretation and genomic reports to demonstrate the validity of whole genome sequencing to support clinicians and their patients throughout all of the steps of the treatment journey from diagnosis to therapy selection and specialty consultation, eventually leading to better health outcomes. "Whole genome sequencing for cancer patients can mean all the difference when determining the best treatment plan in a timely manner. By starting with whole genome sequencing, we can offer pharmacogenomics reports available in minutes, determining the best drugs on the market and any resistance to existing therapies. This project with the Italian government will increase access to personalized medicine options for people with High Grade Serous Ovarian Cancer," said Mattia Capulli, PhD, Co-founder and CSO of Dante Genomics and Associate Professor of Human Embryology and Histology at the University of L'Aquila in Italy. The 36-month project has the ambition to set a proof of concept that demonstrates how a deep integration of genomics and bioinformatics in the treatment of oncology patients brings a dramatic improvement of cancer treatment outcomes. About Dante Genomics Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and software. The Company uses its platform to deliver better patient outcomes, prevention, enhanced diagnostics and personalized medicine. The Company's assets include one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing. Contact: Laura D'Angelo VP of Investor Relations ir@dantelabs.com +39 0862 191 0671

100 Deals associated with University of L'Aquila

100 Translational Medicine associated with University of L'Aquila

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 09 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

UniPR-1331 ( EphA2 )	Solid tumor More	Preclinical
KPT-185 ( XPO1 )	Prostatic Cancer More	Preclinical
KPT-127 ( XPO1 )	Prostatic Cancer More	Pending
KPT-205 ( XPO1 )	Prostatic Cancer More	Pending
SEP 155342	MRSA - Methicillin resistant Staphylococcus aureus infection More	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis